RAMM Pharma Corp.'s Notification on Postal Service Delays
In light of current disruptions affecting postal services, RAMM Pharma Corp. (CSE: RAMM) has communicated important updates to its shareholders. The company, known for its innovative cannabinoid pharmacology, wants to ensure that all shareholders are informed about the implications of the ongoing Canada Post strike. Despite the recent announcement of partial postal service resumption, there may still be unexpected delays in mail deliveries.
Challenges with Meeting Materials
The meeting materials concerning the upcoming Special Meeting of Shareholders can be found on RAMM's SEDAR+ profile. Although these materials have been dispatched in accordance with regular procedures, there exists a risk that they may not reach shareholders in time due to the ongoing disruptions in postal services.
Options for Registered Shareholders
For registered shareholders—those who hold shares directly rather than through intermediaries—there is an opportunity to inquire about control numbers or to seek assistance with voting. They can utilize the “Chat with Odyssey Trust” feature online or contact Odyssey Trust Company directly for support. The contact numbers provided are available for shareholders from both North America and beyond.
Instructions for Beneficial Shareholders
Beneficial shareholders, who invest through brokerage firms or other such intermediaries and have yet to receive their meeting information, should reach out to their respective brokers to procure the necessary proxy materials.
Overview of RAMM Pharma Corp.
RAMM Pharma is actively involved in the development of cannabinoid-based products, emphasizing research in pharmacology and formulation for cannabis and hemp. The company's operations span several international markets, establishing it as a key player in this industry.
European Operations
In Europe, RAMM operates vertically integrated facilities in Italy and Poland, focusing on extraction and processing. Its subsidiary, Canapar Corp., plays a significant role in these functions. Additionally, RAMM’s other subsidiary, HemPoland, stands as a licensed producer and distributor of various hemp products, including its distinguished CannibiGold product line. This diverse structure enables RAMM Pharma to cater to a broad array of markets effectively.
Contact Information for Further Inquiries
For anyone seeking additional information about the company or its operations, RAMM Pharma encourages inquiries to be directed to José Roldan, the Interim CFO, available at their provided contact number. Questions regarding company operations or shareholder assistance can also be illuminated through the company's official channels.
Frequently Asked Questions
What is the main impact of the Postal Service disruptions?
The disruption affects the timely delivery of meeting materials and shareholder communications, leading to potential delays in receiving important information.
How can shareholders obtain the meeting materials?
Shareholders can access meeting materials through RAMM Pharma's SEDAR+ profile or request assistance directly from Odyssey Trust Company.
What should beneficial shareholders do if they didn’t receive their materials?
Beneficial shareholders are encouraged to contact their brokerage firms to request their proxy materials for the upcoming meeting.
Where does RAMM Pharma operate?
RAMM Pharma has operations in several international locations, notably in Europe with significant facilities in Italy and Poland.
Who should shareholders contact for more information?
Shareholders are advised to reach out to José Roldan, Interim CFO, for any inquiries, or utilize the online features provided by Odyssey Trust Company.
